FGFR1 OP (N371) Antibody

貨號 Cat. No.

BS1123

規格 Size

100μg

品牌 Brand

Bioworld

Description

stock

Host: Rabbit

Reactivity: Human,Mouse,Rat

 

Product

1 mg/ml in Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.2.

Purification & Purity

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).

Specificity

FGFR1OP (N371) antibody detects endogenous levels of FGFR1OP protein.

Applications (Recommended Dilutions)

WB: 1:500~1:1000 IHC: 1:50~1:200 IF: 1:50~1:200

Western Blot(WB)

Western blot (WB) analysis of FGFR1OP (N371) antibody in extracts from HepG2 cells.

Immunohistochemistry (IHC)

Immunohistochemistry (IHC) analyzes of FGFR1OP (N371) antibody in paraffin-embedded human breast carcinoma tissue.

Storage&Stability

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Background

Acidic and basic fibroblast growth factors (FGFs) are members of a family of multifunctional polypeptide growth factors that stimulate proliferation of cells of mesenchymal, epithelial and neuroectodermal origin. Like other growth factors, FGFs act by binding and activating specific cell surface receptors. These include the Flg receptor or FGFR-1, the Bek receptor or FGFR-2, FGFR-3, FGFR-4, FGFR-5 and FGFR-6. These receptors usually contain an extracellular ligand-binding region containing three immunoglobulin-like domains, a transmembrane domain and a cytoplasmic tyrosine kinase domain. The gene encoding human Flg maps to chromosome 8p11 and is alternatively spliced to produce several isoforms. Mutations in Flg are associated with Pfeiffer syndrome, a skeletal disorder characterized by craniosynostosis with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly.

詢價 / 洽詢此產品